There are two pieces of good news for embryonic stem cell science in this report from the The Australian. Firstly, a Melbourne company is allowing free, unconditional access to a new embryonic stem cell line, with more to come in the future: "The company planned to release five more stem-cell lines over the next two years." This is an interesting varient on open source development strategies; the company plans to profit indirectly from its altruism. Secondly, this line only cost $100,000 to develop! This comparatively low price point (itself a sign of advancing technological prowess in the field) indicates that we should be seeing many more lines becoming available in the future - an essential condition for real progress in regenerative medicine.